Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases. The ACRS news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates, and investor events drawn from press releases and regulatory disclosures.
Recent Aclaris news has focused on its immunology pipeline, including ATI-2138, a potent and selective oral ITK/JAK3 inhibitor, and its antibody franchise targeting TSLP and IL-4/IL-13 pathways. The company has reported positive Phase 2a results for ATI-2138 in moderate-to-severe atopic dermatitis, initiation and progress of a Phase 2 trial of its anti-TSLP monoclonal antibody bosakitug (ATI-045) in atopic dermatitis, and Phase 1a and Phase 1b development of its bispecific anti-TSLP/IL-4Rα antibody ATI-052, including a Phase 1b proof-of-concept trial in atopic dermatitis.
Investors and followers of ACRS can use this news feed to track key milestones such as interim and top line clinical results, updates on additional indications for ATI-2138, and timelines for proof-of-concept and later-stage trials. The page also captures corporate developments, including quarterly and year-to-date financial results, cash runway commentary, index inclusions such as the Nasdaq Biotechnology Index, and participation in healthcare and biotechnology conferences and R&D Day events.
By reviewing the ACRS news page regularly, readers can follow how Aclaris communicates progress across its oral kinase inhibitor and biologics franchises, how it describes the evolution of its multi-stage portfolio, and how financial and strategic updates align with its stated focus on patients with immuno-inflammatory diseases who lack satisfactory treatment options.
Aclaris Therapeutics (NASDAQ: ACRS) will participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026 at 12:00 PM EDT.
CEO Dr. Neal Walker and senior leaders will join a fireside chat; a live webcast and archived replay will be available on the company website for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) presented Phase 2a ePoster results for oral ATI-2138 at the 2026 AAD meeting showing rapid, sustained improvements in atopic dermatitis measures at week 12.
Key week-12 outcomes for 10 mg BID included EASI -77%, BSA -70%, PP-NRS -50%, POEM -55%, and DLQI -65%, plus near-complete ITK occupancy and multi-pathway modulation.
Aclaris Therapeutics (NASDAQ: ACRS) announced an ePoster presenting previously unreported results from its open-label Phase 2a trial of ATI-2138 for moderate-to-severe atopic dermatitis at the 2026 AAD Annual Meeting in Denver, CO on March 20, 2026.
ATI-2138 is described as an investigational oral covalent inhibitor targeting ITK and JAK3. The poster lists Aclaris and Mount Sinai authors and will be available electronically during the meeting.
Aclaris Therapeutics (NASDAQ: ACRS) completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis, enrolling 109 patients. Top-line results are expected in the fourth quarter of 2026.
The trial's primary endpoint is percent change from baseline in EASI at week 24; secondary endpoints include EASI-50/75/90, IGA, BSA, and PP-NRS. Safety, PD biomarkers, and PK will be assessed. The company cites a 23-day natural half-life and potential dosing convenience as product attributes.
Aclaris Therapeutics (NASDAQ: ACRS) will participate in the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026 at 1:40 PM EDT. CEO Dr. Neal Walker and senior leaders will join a fireside chat. A live and archived webcast will be available on the company Events page for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 and full‑year 2025 results and provided a corporate update highlighting clinical progress across its biologics and oral ITK programs. Key milestones include positive interim Phase 1a SAD/MAD results for ATI‑052, Phase 1b POC trials initiated with top‑line readouts expected H2 2026, an IND filing for ATI‑9494 targeted H2 2026, promising preclinical hair‑regrowth data for ATI‑2138, cash of $151.4M and a stated runway into H2 2028.
Aclaris Therapeutics (NASDAQ: ACRS) has initiated a randomized, double-blind, placebo-controlled Phase 1b proof-of-concept trial of its bispecific anti-TSLP/IL-4Rα antibody ATI-052 in asthma, following a Phase 1b start in atopic dermatitis.
The ~16-patient study (3:1 randomization) will assess safety, tolerability, PK, PD biomarkers including FeNO and blood eosinophils, and FEV1. Top-line results for both POC trials are expected in the second half of 2026, with a Phase 2b program planned for H2 2026.
Aclaris Therapeutics (NASDAQ: ACRS) will participate in two healthcare conferences in February 2026 with senior management presentations and webcasts available.
On Feb 12, 2026 at 2:30 PM EST CEO Dr. Neal Walker will join a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit. On Feb 26, 2026 at 8:40 AM EST President COO Hugh Davis will present at Oppenheimer 36th Annual Healthcare Life Sciences Conference. Webcasts will be available on the company website for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) reported preclinical results showing its oral ITK/JAK3 inhibitor ATI-2138 produced rapid, near-complete, and sustained hair regrowth in a validated murine reversal model of alopecia universalis versus control and ritlecitinib.
At 300 ppm in chow, mean hair regrowth was 37% at week 2, 87% at week 4, and 93% at week 6 for ATI-2138 versus 25%, 48%, and 78% respectively for ritlecitinib. ATI-2138 is highly selective for ITK and JAK3 (>1,000-fold versus other JAKs). Aclaris expects to initiate a Phase 2b trial in H1 2026.
Aclaris Therapeutics (NASDAQ: ACRS) has initiated a randomized (3:1), blinded, placebo-controlled Phase 1b proof-of-concept trial in atopic dermatitis (AD) for ATI-052, a bispecific anti-TSLP/IL-4Rα antibody. The company cited positive Phase 1a interim results showing a strong safety and tolerability profile, extended pharmacokinetics, and concentration-dependent pharmacodynamics at low dose. The Phase 1b AD trial will assess safety, EASI, IGA response, PP-NRS, PK, and PD using lesional and non-lesional skin tape strips. Aclaris expects to start a second Phase 1b POC trial in asthma in Q1 2026 and to report topline results from both POC trials in H2 2026.